Corvus Pharmaceuticals (CRVS) announced new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback